NCT06933277Recruiting
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone (SVd) for the Treatment of Multiple Myeloma Patients
Source: ClinicalTrials.gov · Last updated 10 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy. A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 159 (estimated)
- First submitted
- 3 Apr 2025
- Start date
- 29 Aug 2025
- Primary completion date
- Aug 2028
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Diseases
- Multiple myeloma
- NCT number
- NCT06933277
What you commit to
- Study type: Observational
- Planned participants: 159
- From 29 Aug 2025 to the primary completion date, Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Previous exposure to selinexor.
Who the study is looking for
- Age equal to or greater than 18 years old at the time of SVd initiation
- Signed informed consent (if applicable).
- Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.
- Relapse after one to three lines of therapy.
- Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization)
- Prior treatment with and refractoriness to lenalidomide.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aou Careggi - Sod Ematologia Coordinator of this site? Confirm its status | Florence | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.